AVEO Pharmaceuticals Price to Sales Ratio 2010-2022 | AVEO
Historical PS ratio values for AVEO Pharmaceuticals (AVEO) over the last 10 years. The current P/S ratio for AVEO Pharmaceuticals as of May 27, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| AVEO Pharmaceuticals P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-05-27 |
4.23 |
|
2.34 |
| 2022-03-31 |
5.59 |
$1.81 |
3.09 |
| 2021-12-31 |
4.69 |
$1.27 |
3.69 |
| 2021-09-30 |
6.18 |
$0.77 |
8.00 |
| 2021-06-30 |
6.59 |
$0.47 |
14.00 |
| 2021-03-31 |
7.32 |
$0.29 |
24.90 |
| 2020-12-31 |
5.77 |
$0.27 |
21.15 |
| 2020-09-30 |
5.94 |
$0.28 |
21.13 |
| 2020-06-30 |
5.15 |
$1.74 |
2.96 |
| 2020-03-31 |
3.62 |
$1.74 |
2.08 |
| 2019-12-31 |
6.24 |
$1.81 |
3.44 |
| 2019-09-30 |
8.45 |
$1.88 |
4.50 |
| 2019-06-30 |
6.73 |
$0.48 |
13.90 |
| 2019-03-31 |
8.20 |
$0.47 |
17.31 |
| 2018-12-31 |
16.00 |
$0.44 |
36.47 |
| 2018-09-30 |
33.10 |
$0.33 |
99.38 |
| 2018-06-30 |
22.60 |
$0.52 |
43.57 |
| 2018-03-31 |
29.00 |
$0.52 |
56.11 |
| 2017-12-31 |
27.90 |
$0.76 |
36.59 |
| 2017-09-30 |
36.50 |
$0.77 |
47.21 |
| 2017-06-30 |
22.20 |
$0.51 |
43.28 |
| 2017-03-31 |
5.90 |
$0.51 |
11.57 |
| 2016-12-31 |
5.40 |
$0.38 |
14.03 |
| 2016-09-30 |
8.90 |
$1.01 |
8.79 |
| 2016-06-30 |
9.61 |
$3.54 |
2.71 |
| 2016-03-31 |
9.20 |
$3.54 |
2.60 |
| 2015-12-31 |
12.60 |
$3.35 |
3.76 |
| 2015-09-30 |
12.10 |
$2.73 |
4.43 |
| 2015-06-30 |
17.40 |
$0.24 |
72.39 |
| 2015-03-31 |
14.50 |
$0.57 |
25.29 |
| 2014-12-31 |
8.40 |
$3.51 |
2.39 |
| 2014-09-30 |
11.10 |
$3.55 |
3.13 |
| 2014-06-30 |
18.30 |
$3.44 |
5.31 |
| 2014-03-31 |
14.95 |
$3.15 |
4.75 |
| 2013-12-31 |
18.30 |
$0.25 |
71.83 |
| 2013-09-30 |
20.60 |
$3.77 |
5.46 |
| 2013-06-30 |
25.00 |
$3.94 |
6.34 |
| 2013-03-31 |
73.50 |
$4.31 |
17.04 |
| 2012-12-31 |
80.50 |
$4.45 |
18.10 |
| 2012-09-30 |
104.10 |
$1.13 |
92.06 |
| 2012-06-30 |
121.60 |
$1.73 |
70.30 |
| 2012-03-31 |
124.10 |
$8.50 |
14.60 |
| 2011-12-31 |
172.00 |
$43.95 |
3.91 |
| 2011-09-30 |
153.90 |
$48.36 |
3.18 |
| 2011-06-30 |
206.10 |
$49.54 |
4.16 |
| 2011-03-31 |
133.20 |
$47.40 |
2.81 |
| 2010-12-31 |
146.20 |
$28.92 |
5.06 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.146B |
$0.042B |
|
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
|
